CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 12,369	$ 13,979
Marketable debt securities	2,599	2,987
Receivables	8,511	9,369
Inventories	2,104	2,095
Other current assets	4,538	4,832
Total Current Assets	30,121	33,262
Property, plant and equipment	6,047	6,049
Goodwill	20,500	20,502
Other intangible assets	40,103	42,527
Deferred income taxes	1,418	1,439
Other non-current assets	4,845	5,535
Total Assets	103,034	109,314
Current Liabilities:
Short-term debt obligations	7,522	4,948
Accounts payable	2,944	2,949
Other current liabilities	12,355	13,971
Total Current Liabilities	22,821	21,868
Deferred income taxes	3,809	4,501
Long-term debt	37,450	39,605
Other non-current liabilities	7,309	7,334
Total Liabilities	71,389	73,308
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	43,756	44,361
Accumulated other comprehensive loss	(1,229)	(1,268)
Retained earnings	23,948	23,820
Less cost of treasury stock	(35,187)	(31,259)
Total Bristol-Myers Squibb Company Shareholders’ Equity	31,580	35,946
Noncontrolling interest	65	60
Total Equity	31,645	36,006
Total Liabilities and Equity	$ 103,034	$ 109,314